A few members of Congress have been told to expect the Food and Drug Administration’s safety review of the dangerous and deadly abortion pill mifepristone to be completed by September.
The review is assessing data on mifepristone to determine whether the drug is unsafe and could prompt updates to the FDA’s Risk Evaluation and Mitigation Strategy program to restore the requirement that the pill be dispensed in person at a clinic or physician’s office.
Read Full Article: https://www.lifenews.com/2026/06/25/fda-will-reportedly-conclude-abortion-pill-safety-review-by-september/
